The Health IT Canadian Technology Accelerator in the US is accepting applications for fall 2017.

The Canadian Technology Accelerator helps high-potential, high-growth Canadian technology SMEs seeking to expand to the US through a program of workshops, events, mentorship and business introductions.

BlueOceanNutraSciences Inc. (TSXV:BOC) announced that it has received a Natural Products Number (NPN) from Health Canada for its extended release Omega-3 astaxanthin shrimp oil tablets (“XR tablets”), the World’s first Omega-3 oils in XR tablet form.

The Company’s shrimp oil XR tablets were developed by its joint venture partner, CMAX Technologies Inc. (“CMAX”).

Stéphane Gagné, President and CEO of Ovensa Inc - a CAAP alumni - attended BIO 2017 and contributed this report on the value of the conference to Ontario’s life sciences industry.

ScarX Therapeutics, an OBIO CAAP program alumni, announced today it has completed enrollment for its initial human clinical trial of SCX-001, a first-of-its-kind topical treatment to significantly reduce surgical scarring.

Application deadline: August 10th, 2017 - APPLY HERE

Apply now if you are interested in meeting one-on-one with Forbion Capital Partners, after their "Investor Spotlight" presentation at JLabs on September 6th, 2017.

Application deadline: July 26, 2017 at 2:00pm EDT - APPLY HERE

One month left until the application deadline for the Postdoctoral Scholars 2017 program. 
Please share this message with all current postdoctoral researchers at your institution.

NOVADAQ Technologies Inc. (NASDAQ:NVDQ) (TSX:NDQ) the leading provider of proven comprehensive fluorescence imaging solutions that improve clinical outcomes and reduce healthcare costs in minimally invasive and open surgeries, today announced that it has entered into a definitive arrangement  with Stryker Corporation to acquire all of the issued and outstanding shares of NOVADAQ.

Suzanne was interviewed about her deep career in technology, military, non-profit, health and creative fields.

Rna Diagnostics announced the launch of an international prospective clinical trial to validate the RNA Disruption Assay™ (RDA™) as a tool for treatment management of primary breast cancer.

Proteorex Therapeutics Inc., a 2017 CAAP company, announced a research and development collaboration with Montreal-based Corbin Therapeutics.

Proteocyte Diagnostics hosted their first global Straticyte™ meeting at the 6th World Oral Cancer Congress of the International Academy of Oral Oncology (IAOO) in India  on May 18, 2017.

PanamericanWorld is a Canadian digital online magazine which reaches online communities throughout the Americas, in Spanish, English, and Portuguese.

Grand Challenges Canada, a platform supporting innovation in global health funded by the Government of Canada, has launched a new funding opportunity through its Stars in Global Health program: "Stars in Reproductive, Maternal, Newborn and Child Health (RMNCH)."

Sernova reports on active pharma collaboration, upcoming clinical trial and fertile BD pipeline to advance scale of diabetes and hemophilia programs

TORONTO, June 6, 2017 ‐ Lumira Capital, a leading North American healthcare venture capital firm, announced today that it has launched a new philanthropic initiative whereby the firm’s partners will donate a portion of their profit share from Lumira Capital IV L.P. to up to fifteen leading healthcare foundations in Canada.

The Export Services Branch, Ontario Ministry of International Trade, is organizing a Trade Mission to the RESI Conference, November 15, 2017, Marriott Marquis Hotel, New York City, New York.  This Trade Mission will be able to accommodate a maximum of ten Ontario companies.

Are you a High Potential Canadian ICT or Life Science SME ready to grow in the US Boston Market? We can help.

CTA@Boston is an award-winning program that connects Canadian ICT and Life Science companies to US clients, strategic partners and investors, emphasizing aggressive business development and growth.  

The Canadian Technology Accelerator in Boston (CTA@Boston) is looking for fast growing ICT and Life Science candidates for the Fall 2017 cohort.

Apply Now to CTA@Boston

Application Deadline:  June 12, 2017

Formation Biologics, a clinical stage biopharmaceutical company, today announces the start of a multi-center, Phase I/IIa trial evaluating AVID100 in patients with epidermal growth factor receptor (EGFR)-expressing malignancies. The trial commenced at South Texas Accelerated Research Therapeutics in San Antonio, Texas.

MyndTec Wins Ontario Centres of Excellence's (OCE) $20,000 Accessibility Tech Pitch Competition

Toronto, May 1 2017 Conavi Medical Inc. announced their 510(k) clearance from the FDA for its Foresight ICE System expanded feature set.